Diabetic Neuropathic Pain - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 109 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Diabetic Neuropathic Pain - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Diabetic Neuropathic Pain - Pipeline Review, H2 2014', provides an overview of the Diabetic Neuropathic Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diabetic Neuropathic Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diabetic Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Neuropathic Pain Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Neuropathic Pain - Overview 10
Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis 11
Diabetic Neuropathic Pain - Therapeutics under Development by Companies 12
Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 14
Diabetic Neuropathic Pain - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Diabetic Neuropathic Pain - Products under Development by Companies 18
Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes 19
Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development 20
Bristol-Myers Squibb Company 20
AstraZeneca PLC 21
Eli Lilly and Company 22
BioDelivery Sciences International, Inc. 23
Daiichi Sankyo Company, Limited 24
Acorda Therapeutics, Inc. 25
Astellas Pharma Inc. 26
Glenmark Pharmaceuticals Ltd. 27
KunWha Pharmaceutical Co., Ltd. 28
Mertiva AB 29
Grunenthal GmbH 30
Kyorin Pharmaceutical Co., Ltd. 31
Bial - Portela & Ca, S.A. 32
Lohocla Research Corporation 33
Relmada Therapeutics, Inc. 34
Sphaera Pharma Pvt. Ltd. 35
SK Biopharmaceuticals Co., Ltd. 36
Immune Pharmaceuticals, Inc. 37
AbbVie Inc. 38
Dong-A Socio Group 39
Diabetic Neuropathic Pain - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
duloxetine hydrochloride DR - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
capsaicin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(amitriptyline + ketamine) - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
clonidine hydrochloride - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
eslicarbazepine acetate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
pregabalin ER - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SKL-NP - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
cebranopadol - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
DA-3030 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
AZD-5213 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
GRC-17536 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
mirogabalin - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
BMS-954561 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ABT-639 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ibudilast - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Dextromethadone - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
SPC-612 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NG2-GAD - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
mepivacaine hydrochloride - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Peptide for Methylglyoxal Induced Pains - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
PGN-305 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
AS-1069562 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Kindolor - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
PRTT-200 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Diabetic Neuropathic Pain - Recent Pipeline Updates 86
Diabetic Neuropathic Pain - Dormant Projects 100
Diabetic Neuropathic Pain - Discontinued Products 101
Diabetic Neuropathic Pain - Product Development Milestones 102
Featured News & Press Releases 102
Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 102
Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt 102
Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 103
Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 103
Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds 104
Aug 29, 2012: Janssen Receives FDA Approval For Nucynta Extended-release Oral Tablets For Management Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy 104
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 105
Mar 20, 2012: Astellas Pharma Europe Withdraws Its Applications For Extension Of Indication For Qutenza 106
Feb 22, 2012: Shionogi And Lilly Japan Announce Approval Of Additional Indication For Cymbalta In Japan 106
Feb 08, 2012: Avanir Announces Publication Of Phase III Study Results Of AVP-923 To Treat Diabetic Neuropathic Pain 107
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 109
Disclaimer 109

List of Tables
Number of Products under Development for Diabetic Neuropathic Pain, H2 2014 10
Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Diabetic Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H2 2014 20
Diabetic Neuropathic Pain - Pipeline by AstraZeneca PLC, H2 2014 21
Diabetic Neuropathic Pain - Pipeline by Eli Lilly and Company, H2 2014 22
Diabetic Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2014 23
Diabetic Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 24
Diabetic Neuropathic Pain - Pipeline by Acorda Therapeutics, Inc., H2 2014 25
Diabetic Neuropathic Pain - Pipeline by Astellas Pharma Inc., H2 2014 26
Diabetic Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2014 27
Diabetic Neuropathic Pain - Pipeline by KunWha Pharmaceutical Co., Ltd., H2 2014 28
Diabetic Neuropathic Pain - Pipeline by Mertiva AB, H2 2014 29
Diabetic Neuropathic Pain - Pipeline by Grunenthal GmbH, H2 2014 30
Diabetic Neuropathic Pain - Pipeline by Kyorin Pharmaceutical Co., Ltd.., H2 2014 31
Diabetic Neuropathic Pain - Pipeline by Bial - Portela & Ca, S.A., H2 2014 32
Diabetic Neuropathic Pain - Pipeline by Lohocla Research Corporation, H2 2014 33
Diabetic Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2014 34
Diabetic Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2014 35
Diabetic Neuropathic Pain - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 36
Diabetic Neuropathic Pain - Pipeline by Immune Pharmaceuticals, Inc., H2 2014 37
Diabetic Neuropathic Pain - Pipeline by AbbVie Inc., H2 2014 38
Diabetic Neuropathic Pain - Pipeline by Dong-A Socio Group, H2 2014 39
Assessment by Monotherapy Products, H2 2014 40
Assessment by Combination Products, H2 2014 41
Number of Products by Stage and Target, H2 2014 44
Number of Products by Stage and Mechanism of Action, H2 2014 47
Number of Products by Stage and Route of Administration, H2 2014 49
Number of Products by Stage and Molecule Type, H2 2014 51
Diabetic Neuropathic Pain Therapeutics - Recent Pipeline Updates, H2 2014 86
Diabetic Neuropathic Pain - Dormant Projects, H2 2014 100
Diabetic Neuropathic Pain - Discontinued Products, H2 2014 101